Charles Schwab Investment Management Inc. lifted its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 144.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 390,257 shares of the company's stock after buying an additional 230,820 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.51% of Liquidia worth $3,903,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. Quest Partners LLC purchased a new position in shares of Liquidia in the 2nd quarter worth $27,000. Deuterium Capital Management LLC bought a new position in Liquidia in the 2nd quarter worth $120,000. Clear Harbor Asset Management LLC bought a new position in Liquidia in the 3rd quarter worth $100,000. Signaturefd LLC raised its holdings in Liquidia by 38,400.0% in the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company's stock worth $100,000 after purchasing an additional 9,984 shares during the period. Finally, Ballentine Partners LLC bought a new position in Liquidia in the 3rd quarter worth $110,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
LQDA has been the topic of a number of recent research reports. BTIG Research decreased their target price on Liquidia from $29.00 to $25.00 and set a "buy" rating on the stock in a report on Monday, August 19th. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 target price on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital began coverage on Liquidia in a report on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 target price on the stock. Finally, Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $24.00.
Get Our Latest Analysis on LQDA
Insider Buying and Selling at Liquidia
In related news, CFO Michael Kaseta sold 3,892 shares of the business's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the completion of the sale, the chief financial officer now owns 311,076 shares in the company, valued at approximately $3,456,054.36. The trade was a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rajeev Saggar sold 2,260 shares of the business's stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $25,108.60. Following the completion of the sale, the insider now owns 207,383 shares of the company's stock, valued at $2,304,025.13. The trade was a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,007 shares of company stock worth $245,780 over the last 90 days. Company insiders own 30.10% of the company's stock.
Liquidia Price Performance
Shares of NASDAQ:LQDA traded down $0.09 during trading hours on Friday, hitting $10.92. 472,472 shares of the company's stock traded hands, compared to its average volume of 970,897. Liquidia Co. has a 1 year low of $7.03 and a 1 year high of $16.99. The business has a fifty day moving average price of $10.93 and a 200-day moving average price of $11.23. The firm has a market capitalization of $924.24 million, a P/E ratio of -6.70 and a beta of 0.22.
Liquidia Profile
(
Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Recommended Stories
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.